The mTOR signaling pathway as a treatment target for intracranial neoplasms

Area of Science:

• Oncology
• Molecular Biology
• Neuro-oncology

Background:

• The mammalian target of rapamycin (mTOR) signaling pathway is frequently hyperactivated in both sporadic and hereditary brain tumors.
• While mTOR inhibitors have shown success in epithelial cancers, their application in brain tumors is less established.
• Understanding mTOR's role is crucial for developing effective intracranial cancer treatments.

Purpose of the Study:

• To review the role of mTOR activation in the pathogenesis and growth of human brain tumors.
• To provide context for ongoing clinical trials investigating mTOR inhibitors for brain cancer.
• To highlight the therapeutic potential of targeting mTOR in neuro-oncology.

Main Methods:

• Literature review of studies on mTOR signaling in brain tumors.
• Analysis of clinical trial data involving mTOR inhibitors in various cancers.
• Synthesis of information on brain tumor pathogenesis and growth mechanisms related to mTOR.

Main Results:

• mTOR pathway hyperactivation is a common feature in brain tumor development and progression.
• Clinical data from other cancer types suggest mTOR inhibitors can be effective.
• Limited but emerging data indicate potential efficacy of mTOR inhibitors in specific brain tumor contexts.

Conclusions:

• Targeting the mTOR pathway represents a promising therapeutic strategy for human brain tumors.
• Further research and clinical trials are warranted to optimize the use of mTOR inhibitors in neuro-oncology.
• The review provides a foundation for understanding mTOR's significance in brain tumor treatment strategies.